Sentences with phrase «dysfunction in human disease»

We will seek investigators that span a range of metabolism expertise, with an emphasis on interdisciplinary and collaborative - minded researchers passionate about exploring the basic molecular and mechanistic underpinnings of cellular metabolism and its dysfunction in human disease.

My laboratory is an interdisciplinary team of scientists driven to understand the biochemical underpinnings of mitochondrial dysfunction in human diseases.

We are an interdisciplinary team of scientists driven to understand the biochemical underpinnings of mitochondrial dysfunction in human diseases.

Not exact matches

«The imaging technique could shed light on the immune dysfunction that underpins a broad range of neuroinflammatory diseases, such as Alzheimer's disease, depression, post-traumatic stress disorder and addiction,» said Christine Sandiego, PhD, lead author of the study and a researcher from the department of psychiatry at the Yale School of Medicine in New Haven, Conn. «This is the first human study that accurately measures this immune response in the brain.

The team at UF's Powell Center for Rare Disease Research and Therapy conducted the first in - human study of gene therapy to treat respiratory dysfunction in patients with infantile onset Pompe.

In humans, the cerebellum's extensive connectivity with the rest of the brain suggests it does far more than learn motor skills: it has been shown to have a part in both perception and cognition, with recent work linking cerebellar dysfunction to such complex diseases as schizophrenia and autisIn humans, the cerebellum's extensive connectivity with the rest of the brain suggests it does far more than learn motor skills: it has been shown to have a part in both perception and cognition, with recent work linking cerebellar dysfunction to such complex diseases as schizophrenia and autisin both perception and cognition, with recent work linking cerebellar dysfunction to such complex diseases as schizophrenia and autism.

Human iPS cell - derived hepatocytes differentiated with our robust differentiation protocol and cultured using our novel maintenance medium provide an inexhaustible, consistent supply of functional hepatocytes that can be used to advance the understanding of diseases related to dysfunction in liver metabolism, including NAFLD / NASH, type 2 diabetes, and metabolic syndrome.

Human iPS cell - derived hepatocytes differentiated with our robust differentiation protocol and cultured using a novel maintenance medium provide an inexhaustible, consistent supply of functional hepatocytes that can be used to advance the understanding of diseases related to dysfunction in liver metabolism, including NAFLD / NASH, type 2 diabetes, and metabolic syndrome.

Moreover, PHENONIM - ICS is involved in European projects presenting a strong impact on human health: Interreg CARDIOGENE (Genetic mechanisms of cardiovascular diseases), GENCODYS (Genetic and epigenetic networks involved in cognitive dysfunctions), AgedBrainSYSBIO (Basic studies of brain aging), as well as projects in partnership with industry: MAGenTA (an Industrial Strategic Innovation project supported by Bpifrance about the treatment of major urogenital diseases) and CanPathPro (H2020 program), to develop a predictive modeling platform of signaling pathways involved in cancers.

Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transporters

Dr. Falk is also PI of an NIH, pharma, and philanthropic funded translational research laboratory group at CHOP that investigates the causes and global metabolic consequences of mitochondrial disease, as well as targeted therapies, in C. elegans, zebrafish, mouse, and human tissue models of genetic - based respiratory chain dysfunction, and directs multiple clinical treatment trials in mitochondrial disease patients.

By reprogramming human skin cells and other cells from patients with neurologic and psychiatric diseases into induced pluripotent stem cells (iPSCs) and induced neurons (iN), his work seeks to decipher the progression and mechanisms that lead to brain cell dysfunction.

Exposure to BPA, used in the manufacture of polycarbonate and other plastics, has been shown to cause reproductive problems and erectile dysfunction, and has been linked with cardiovascular disease and diabetes in humans.

«Problems ranging from autoimmune disease to clinical depression and simple obesity may in fact be linked to immune dysfunction that begins with a «failure to communicate» in the human gut, the scientists say.

Feline Dementia, also called feline cognitive dysfunction, is a condition similar to Alzheimer's disease in humans.

Canine cognitive dysfunction syndrome has similarities to Alzheimer's disease that impacts humans and can cause confusion, disorientation, memory loss and changes in personality.

Canine Cognitive Dysfunction Syndrome (CDS) is akin to Alzheimer's disease in humans.

Canine Cognitive Dysfunction (CCD), or canine geriatric dementia, acts in a very similar way as Alzheimer's disease does in humans, and can create a heavy burden on

Cognitive processing naturally slows down somewhat in aging, your older dog may take a few more repetitions before getting a new trick, or spend a little longer figuring out a new puzzle toy, but more serious confusion and disorientation may be related to a disorder known as Canine Cognitive Dysfunction or CCD, a canine disorder similar to Alzheimer's disease in human beings.

Similar to Alzheimer's Disease in humans, cognitive dysfunction leads to memory loss, confusion, and depression.

In some cases, older dogs start eliminating in the home when suffering from canine cognitive dysfunction, a condition similar to Alzheimer's disease in humanIn some cases, older dogs start eliminating in the home when suffering from canine cognitive dysfunction, a condition similar to Alzheimer's disease in humanin the home when suffering from canine cognitive dysfunction, a condition similar to Alzheimer's disease in humanin humans.

By helping to rid the brain of destructive free radicals, selegiline hydrochloride has proven useful in treating Parkinson's disease in humans as well as canine cognitive dysfunction (senility) in dogs.

Cognitive dysfunction syndrome is caused by degenerative changes in the brain, changes very similar to those seen in humans with Alzheimer's disease.

Canine cognitive dysfunction syndrome (CDS) is a gradual neurological degenerative disorder of senior dogs that is often compared to dementia, senility and even Alzheimer's disease in humans.

In human healthcare, preventive medicine is a very important tool for detecting underlying disease such as diabetes, heart failure, and liver dysfunction.

Some versions of human medications have received approval by the Food and Drug Administration for specific mental - health uses in pets, including the antidepressant clomipramine (Clomicalm) for separation anxiety in dogs, the sedative dexmedetomidine (Sileo) for dogs with noise - aversion problems, and selegiline (Anipryl), a drug often used to treat Parkinson's disease in humans, for canine cognitive dysfunction.

Canine cognitive dysfunction (CCD), also called cognitive dysfunction syndrome, is comparable to Alzheimer's disease in humans.